多發性硬化症治療藥

多發性硬化症治療藥 是由出版商Global Industry Analysts, Inc.在2010年04月所出版的。 這份英文市場調查報告書包含Pages: 430 價格從美金3950起跳。

簡介

本報告書為全球多發性硬化症治療藥市場的相關分析，包含該疾病罹患率與治療法、藥劑開發管道以及，涉足市場的主要企業之概要與各國各市場動向交織而成，概述如下。

第1章 導論、調査方法、產品定義

第2章 總綱

• 市場重點
• 市場概要
  • 增加了的多發性硬化症罹患率
  • 市場中多發性硬化症的治療藥
  • 高度為被滿足的需求與豊富的管道
  • 課題
• 市場動向
  • 干擾型藥劑為主流
  • 銷售量下跌是現在治療藥所不可避免的
  • 對Betaseron而言的嚴峻時刻
  • 管道的口服藥改變了市場動向
  • 競爭環境
• 多發性硬化症：藥劑管道
  • 近年的實驗活動：概要
  • 多發性硬化症疫苗
• 產品概要
  • 定義
  • 多發性硬化症原因
  • 多發性硬化症的各種形態
  • 病理學
• 近年的業界活動
• 主要企業
  • Bayer Schering Pharma AG
  • Biogen Idec Inc.
  • Elan Pharmaceuticals, Inc.
  • Genzyme Corp.
  • Merck Serono SA
  • Novartis AG
  • Sanofi-Aventis SA
  • Teva Pharmaceuticals Industries Limited
• 世界市場前景

第3章 市場

• 美國
• 日本
• 歐洲
• 其他地區

第4章 競爭環境

目錄

Abstract

This report analyzes the worldwide markets for Multiple Sclerosis Therapeutics in US$ Billion. The report provides separate comprehensive analytics for the US, Japan, Europe and Rest of World. Annual estimates and forecasts are provided for each region for the period 2006 through 2015. The report profiles 45 companies including Bayer Schering Pharma AG, Biogen Idec Inc., Elan Pharmaceuticals, Inc., Genzyme Corp, Merck Serono SA, Novartis AG, Sanofi-Aventis SA, and Teva Pharmaceuticals Industries Limited. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

• Study Reliability and Reporting Limitations
• Disclaimers
• Data Interpretation & Reporting Level
• Quantitative Techniques & Analytics
• Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. MARKET HIGHLIGHTS

• Market Snapshots
• Market Drivers
• Market Restraints
• Major Players

2. MARKET OVERVIEW

• Increasing Prevalence of Multiple Sclerosis
• Table 1: World Multiple Sclerosis Prevalence in Thousands by Select Countries for Years 2001 through 2010 (includes corresponding Graph/Chart)
• Table 2: Prevalence by Types of Multiple Sclerosis (includes corresponding Graph/Chart)
• MS Therapeutics in the Market
• Key Multiple Sclerosis Drugs
• Interferon Drugs
• Beta Interferon Drugs in Multiple Sclerosis Treatment
• Non-Interferon Drugs
• Non-Interferon Drugs in Multiple Sclerosis Treatment
• High Unmet Need and Rich Pipeline to Expand MS Market
• Challenges Ahead

3. MARKET TRENDS

• Interferon-based Drugs Dominate Multiple Sclerosis Market
• Sales Dip Inevitable for Current Therapies
• Tough Times Ahead for Betaseron
• Oral Drugs in Pipeline to Alter Market Dynamics in MS Therapies
• Competitive Landscape
• Table 3: Global Multiple Sclerosis Market by Leading Drugs (2008 & 2009): Percentage Share Breakdown for Copaxone, Avonex, Rebif, Betaseron, and Tysabri (includes corresponding Graph/Chart)

4. MULTIPLE SCLEROSIS - DRUG PIPELINE

• Recent Clinical Trial Activity - An Overview
• Drugs Under Development for Treating Multiple Sclerosis
• FTY 720 (Fingolimod)
• Mylinax
• Laquinimod
• Alemtuzumab
• Teriflunomide
• BG-12 (Oral Fumarate)
• MN-166
• Rituxan/MabThera (Rituximab)
• Vaccines for Multiple Sclerosis

5. PRODUCT OVERVIEW

• Definition
• Causes of Multiple Sclerosis
• Different Forms of Multiple Sclerosis
• Pathology

6. RECENT INDUSTRY ACTIVITY

• Acorda Therapeutics Obtains FDA Approval for Fampridine-SR to treat Multiple Sclerosis
• Novartis Obtains Priority Review Status for Oral Fingolimod from US FDA
• Copaxone Receives FDA Approval for Patients with First Clinical Episode Suggestive of MS
• Novartis Obtains FDA Approval for Extavia
• Merck Serono Collaborates with Brigham and Women' s Hospital to Extend Multiple Sclerosis Research
• Merck Serono Announces Encouraging Phase III Results of Oral Mylinax
• Merck Serono Acquires Rights to Apitope' s Multiple Sclerosis Approach
• Teva and Active Biotech Obtains Fast Track Status from FDA for Oral Laquinimod
• Genzyme Signs an Agreement with Bayer Healthcare
• EMD Serono to Set Up Research Facility in Massachusetts
• EMD Serono Enters into a Partnership with Fast Forward
• Biogen Idec Secures US-FDA Approval for Production Process of TYSABRI®
• Biogen Idec Secures Fast Track Designation from US-FDA for PEGylated Interferon Beta-1a
• Bayer Schering Pharma Receives SFDA of China Approval for Betaferon®
• Merck Serono Signs an Agreement with Bionomics
• Orasi Medical Establishes New Office in Tokyo
• Merck Serono and Ambrx to Extend Collaboration for Multiple Sclerosis
• Kineta Acquires Novel Therapeutic Compounds from Airmid
• MediciNova Enters into Agreement with Avigen
• Biogen Idec Takes Over Facet Biotech
• Teva Pharmaceutical Industries to Take over CoGenesys
• Merck Serono Introduces RebiSmartTM Electronic Injection Device
• Bayer to Launch Betaferon Titration Pack
• MediciNova Announces Phase II Clinical Trial Results of MN-166
• The Myelin Repair Foundation Signs Strategic Deal with Dalton Pharma Services
• Acorda Therapeutics Takes Over Neurorecovery
• Bayer to Introduce 30-Gauge Needle for Betaferon®
• Biogen Idec Commences Late-Stage Trial of Oral Compound Bg-12
• Bayer Acquires Biologics Manufacturing Plant from Novartis

7. FOCUS ON SELECT PLAYERS

• Bayer Schering Pharma AG (Germany)
• Biogen Idec Inc. (US)
• Elan Pharmaceuticals, Inc. (US)
• Genzyme Corp. (US)
• Merck Serono SA (Switzerland)
• Novartis AG (Switzerland)
• Sanofi-Aventis SA (France)
• Teva Pharmaceuticals Industries Limited (Israel)

8. GLOBAL MARKET PERSPECTIVE

• Table 4: World Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Geographic Region - US, Japan, Europe and Rest of World- Markets Independently Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)
• Table 5: World 10-year Perspective for Multiple Sclerosis Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)
• Table 6: World Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Leading Drugs - Copaxone, Avonex, Rebif, Betaseron, Tysabri, and Other Drugs Independently Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)
• Table 7: World 10-year Perspective for Multiple Sclerosis Therapeutics by Leading Drugs - Percentage Breakdown of Dollar Sales for Copaxone, Avonex, Rebif, Betaseron, Tysabri, and Other Drugs for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

• A. Market Analysis
  • Overview
  • Table 8: US Multiple Sclerosis Prevalence in Thousands for Years 2001 through 2010 (includes corresponding Graph/Chart)
  • Strategic Corporate Developments
  • Key Players
  • Biogen Idec, Inc.
  • Elan Pharmaceuticals, Inc.
  • EMD Serono, Inc.
  • Genzyme Corp.
• B. Market Analytics
  • Table 9: US Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics Market Analyzed with Annual Sales Figures in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)

2. JAPAN

• A. Market Analysis
  • Overview
  • Table 10: Japanese Multiple Sclerosis Prevalence in Thousands for Years 2001 through 2010 (includes corresponding Graph/Chart)
  • Strategic Corporate Development
• B. Market Analytics
  • Table 11: Japanese Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics Market Analyzed with Annual Sales Figures in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)

3. EUROPE

• A. Market Analysis
  • Overview
  • Table 12: Multiple Sclerosis Prevalence in Select European Countries for Years 2001 through 2010 (includes corresponding Graph/Chart)
  • Low Penetration to Fuel Growth in European MS DMDs Market
  • Oral Medication for MS in Near Future
  • Strategic Corporate Development
  • Key Players
  • Bayer Schering Pharma AG (Germany)
  • Merck Serono SA (Switzerland)
  • Novartis AG (Switzerland)
  • Sanofi-Aventis SA (France)
• B. Market Analytics
  • Table 13: European Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics Market Analyzed with Annual Sales Figures in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)

4. REST OF WORLD

• A. Market Analysis
  • Overview
  • Increasing Incidence of Multiple Sclerosis in Canada
  • Strategic Corporate Developments
  • Key Player
  • Teva Pharmaceuticals Industries Limited (Israel)
• B. Market Analytics
  • Table 14: Rest of World Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics Market Analyzed with Annual Sales Figures in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

相關商品

神經疾病相關市場調查報告書

中樞神經系統(CNS)的罕見疾病治療市場(∼2017年):AMR101和ACR16等新藥提供治療可供選擇，支援亨丁頓舞蹈症市場區隔
Orphan Diseases Therapeutics in CNS to 2017 - Novel Agents such as AMR101 and ACR16 to Provide Treatment Options and Boost the Huntington's Disease Segment
價格 : US $ 3500
出版日期 : 2012年04月

神經保護：醫療藥品・市場・企業
Neuroprotection - Drugs, Markets and Companies
價格 : US $ 5000
出版日期 : 2012年04月

阿茲海默症：新藥・市場・企業
Alzheimer disease - new drugs, markets and companies
價格 : US $ 3500
出版日期 : 2012年04月

Global Industry Analysts, Inc.發行的製藥相關市場調查報告書

減肥商品的全球市場

Weight Control Products

價格 : US $ 4500

出版日期 : 2012年04月

全球人體疫苗市場

Human Vaccines

價格 : US $ 4500

出版日期 : 2012年03月

醫藥品受託製造(PCM)的全球市場

Pharmaceutical Contract Manufacturing

價格 : US $ 4500

出版日期 : 2012年03月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!